Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel

The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In this work, we evaluate the neutralizing activity of the following HIV-1 bNAbs: VCR07-523, N6, PGDM1400, CAP256-VRC26.25, 10-1074, PGT128, 10E8, and DH511.11P, which are directed to different Env surface...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2022-08, Vol.14 (9), p.1910
Main Authors: Kochina, Evgeniya A, Urusov, Felix A, Kruglov, Artem A, Glazkova, Dina V, Shipulin, German A, Bogoslovskaya, Elena V
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Antibodies
Binding sites
broadly neutralizing antibodies
Control
Drug resistance
Drug therapy, Combination
Env
Epitopes
Health aspects
HIV
HIV (Viruses)
HIV-1
Human immunodeficiency virus
Laboratories
PGDM1400
PGT128
Pharmaceutical research
Proteins
Reagents
Testing
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In this work, we evaluate the neutralizing activity of the following HIV-1 bNAbs: VCR07-523, N6, PGDM1400, CAP256-VRC26.25, 10-1074, PGT128, 10E8, and DH511.11P, which are directed to different Env surface epitopes. We used the global panel of HIV-1 pseudoviruses to analyze the bNAbs’ potency and chose the most potent ones. To achieve maximum neutralization breadth and minimum IC50 concentration, the most effective antibodies were tested in double and triple combinations. Among the doubles, the combinations of N6+PGDM1400 and N6+PGT128 with IC50 ≤ 0.3 µg/mL proved to be the most effective. The most effective triple combination was N6+PGDM1400+PGT128. Our data demonstrate that this combination neutralizes pseudoviruses of the global HIV-1 panel with IC50 ≤ 0.11 µg/mL and IC80 ≤ 0.25 µg/mL.
ISSN:1999-4915
1999-4915
DOI:10.3390/v14091910